Insider Selling: Alphatec (NASDAQ:ATEC) CEO Sells $1,896,000.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 100,000 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $18.96, for a total value of $1,896,000.00. Following the transaction, the chief executive officer owned 5,364,078 shares of the company’s stock, valued at approximately $101,702,918.88. This trade represents a 1.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Patrick Miles also recently made the following trade(s):

• On Wednesday, October 1st, Patrick Miles sold 100,000 shares of Alphatec stock. The shares were sold at an average price of $13.96, for a total value of $1,396,000.00.
• On Tuesday, September 2nd, Patrick Miles sold 300,000 shares of Alphatec stock. The stock was sold at an average price of $15.73, for a total value of $4,719,000.00.

Alphatec Stock Up 1.5%

NASDAQ:ATEC opened at $19.80 on Friday. The stock has a 50-day simple moving average of $15.63 and a 200 day simple moving average of $13.56. Alphatec Holdings, Inc. has a 52-week low of $8.18 and a 52-week high of $20.17. The company has a market cap of $2.94 billion, a PE ratio of -17.52 and a beta of 1.17. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. The company’s revenue was up 30.4% compared to the same quarter last year. During the same period last year, the company earned ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Alphatec

A number of hedge funds and other institutional investors have recently bought and sold shares of ATEC. Osterweis Capital Management Inc. bought a new stake in Alphatec in the second quarter valued at approximately $37,000. Larson Financial Group LLC acquired a new position in shares of Alphatec during the 1st quarter worth approximately $54,000. Nisa Investment Advisors LLC raised its stake in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 1,045 shares during the period. FORA Capital LLC acquired a new stake in Alphatec during the 1st quarter valued at $102,000. Finally, PKS Advisory Services LLC acquired a new stake in Alphatec during the 1st quarter valued at $111,000. Institutional investors own 66.35% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on ATEC. Weiss Ratings restated a “sell (d-)” rating on shares of Alphatec in a report on Tuesday, October 14th. Wells Fargo & Company increased their price objective on shares of Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. HC Wainwright lifted their target price on Alphatec from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Stifel Nicolaus began coverage on Alphatec in a report on Tuesday, October 28th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Needham & Company LLC raised their price target on Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus price target of $22.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.